VVigilance Weekly공개 리포트 보기
← 이번 주 리포트
tofacitinib우선순위 낮음근거 검토기타

LITERATURE DETAIL · PMID 42562116

Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study.

Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study.

저자
Joana Camões Neves, Dalila Costa, Margarida Cristiano, Francisco Portela, Ana Rita Fernandes, Samuel Fernandes
저널
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
공개일
2026 Aug 06
연구 유형
기타
DOI
10.1016/j.cgh.2026.07.020

문헌 요약

Despite the progress in advanced therapies (AT) for ulcerative colitis (UC), selecting a second-line treatment after failure remains challenging. Recent guidelines recommend upadacitinib, tofacitinib or ustekinumab as high-efficacy options after prior AT failure. However, real-world comparative data among these three agents are lacking. Retrospective mult…

PV 검토 포인트

누적 안전성 근거로 분류하고 기존 시그널과의 일관성을 확인합니다.

PubMed에서 원문 정보 보기